MHMariana Hoffman

Mariana Hoffman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mariana Hoffman has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Elizabeth Holland

    Respiratory Research@Alfred, Monash University, Melbourne, Australia; Physiotherapy, Alfred Health, Melbourne, Australia; Institute for Breathing and Sleep, Melbourne, Australia

    8 shared publications
  • Angela T. Burge

    Respiratory Research@Alfred, School of Translational Medicine, Monash University, Melbourne, VIC, Australia

    3 shared publications
  • Anne E. Holland

    Respiratory Research@Alfred, School of Translational Medicine, Monash University, Melbourne, VIC, Australia

    3 shared publications
  • Janet Bondarenko

    Respiratory Research@Alfred, Monash University, Melbourne, Australia; Physiotherapy, Alfred Health, Melbourne, Australia

    3 shared publications
  • Magnus Ekström

    Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine, Allergology and Palliative Medicine, Lund, Sweden

    3 shared publications
  • Angela T. Burge

    Respiratory Research@Alfred, Monash University, Melbourne, Australia; Physiotherapy, Alfred Health, Melbourne, Australia; Institute for Breathing and Sleep, Melbourne, Australia

    2 shared publications

Latest Publications

  • Open Access

    Experiences of using portable oxygen concentrators delivering oxygen or air among people with fibrotic interstitial lung disease in Australia: a qualitative study

    by Mariana Hoffman, Gabriella Tikellis, Joanna Y T Lee, Ching Shan Wan, Yet Khor, Nicole Sl Goh, Ian N Glaspole, Jyotika D Prasad, Natasha Smallwood, Christine F McDonald, et al.

    Objectives: Ambulatory oxygen therapy (AOT), defined as the use of oxygen during activities of daily living and exercise, may be prescribed to optimise quality of life and physical activity in people with fibrotic interstitial lung disease (fILD) with exertional hypoxaemia. The aim of this study was to compare patient experiences of ambulatory therapy with oxygen or air delivered via an identical portable oxygen concentrator (POC) in order to understand perceptions of therapy in both active and sham conditions. Design: A qualitative study using semistructured interviews with open-ended questions was conducted over the telephone. Setting: Participants data were used from a 6-month clinical trial of AOT ( NCT03737409 ) in three hospitals in Australia. Participants: Included participants were randomised 1:1 to receive AOT using a POC (oxygen group) or sham therapy using an identical POC delivering air (air group). Participants were instructed to use the POC whenever they were physically active over 6 months. Participants were blind to group allocation. Interviews were conducted after the intervention period and were recorded and transcribed verbatim, and thematic analysis was used to report on experiences. Results: 23 participants with fILD agreed to be interviewed (12 oxygen group, 11 air group). Participants presented with moderate to severe fILD. Four major themes with subthemes were identified in both groups: benefits of POC use, negative aspects of POC use, equipment features, personal decisions about POC use. Themes and experiences did not differ between oxygen and air groups. Conclusions: POC use provides benefits and challenges. Shared decision-making and consideration of the balance between perceived benefits and harms are required when prescribing this therapy. Trial registration number: NCT03737409 .

  • Open Access

    Products, Performance, and Technological Development of Ambulatory Oxygen Therapy Devices: Scoping Review

    by Shohei Kawachi, Mariana Hoffman, Lorena Romero, Magnus Ekström, Jerry A Krishnan, Anne E Holland

    Background: Ambulatory oxygen therapy is prescribed for patients with chronic lung diseases who experience exertional hypoxemia. However, available devices may not adequately meet user requirements, and their performance characteristics are heterogeneous. Objective: This study aims to identify devices available for delivery of ambulatory oxygen therapy, the technologies that they use to generate oxygen, the performance characteristics of each device, and the development status. Methods: We used medical and engineering databases to identify peer-reviewed papers (eg, MEDLINE, IEEE). Gray literature was used to identify additional descriptions of ambulatory oxygen devices in military medicine, space exploration, or patents. The last search was conducted in September 2025. Documents that described a device that can deliver oxygen in an ambulatory context (defined as weighing less than 10 kg) and were written in English were included. Search results were screened for inclusion by 2 independent reviewers. Data were synthesized by descriptively mapping the performance of each product, the technology used, and the development status of emerging technologies. Results: From 9702 records identified, a total of 166 met eligibility criteria (106 scientific publications and 60 gray literature). We identified 33 portable oxygen concentrators (POCs; 29 commercially available), 10 oxygen cylinders, and 6 portable liquid oxygen (LOX) devices. The POC products showed a trade-off between portability and oxygen delivery capacity (maximum flow rate ranging from 2.0 to 6.0 L/min; device weight ranging from 1.0 to 9.1 kg). Pressure swing adsorption with zeolite was the most common oxygen generation technology in POCs on the market. The mean maximum continuous operating time of POCs was 3.8 hours. Two prototype POCs (maximum flow rate of 4-6 L/min and device weight of 8-9 kg) were developed for space exploration using modified adsorbents. LOX devices were the lightest and had the longest continuous operating time. Innovations in delivery included the downsizing of a POC by using nanozeolite as an adsorbent and pulse oximeter oxygen saturation (SpO2)–targeted automatic titration of oxygen delivery based on the user’s SpO2. Conclusions: This scoping review is the first study to integrate medical, engineering, and gray literature on ambulatory oxygen devices and their development. Although prior literature has narratively explained the products and technologies, no previous research has systematically investigated them. This review showed that POCs available to consumers may not meet the needs of patients in terms of flow rate, portability, and operating time. LOX devices offered superior performance but are limited by high costs. Limitations of this review include the difficulty of comparing product performance across oxygen delivery settings and that the records were largely obtained from English-language sources. Innovation in ambulatory oxygen technology has been limited over the past decade, highlighting urgent need for research and development of new lightweight devices with higher oxygen delivery. Trial Registration: OSF Registries 10.17605/OSF.IO/QS7FX; https://osf.io/qs7fx


  • Open Access

    Factors affecting clinical trial participation in people with interstitial lung disease: a qualitative study

    by Mariana Hoffman, Simone Dal Corso, Jean Bremner, Anne E. Holland

    Background: Clinical trials are the best method for evaluating new treatments for people with interstitial lung disease (ILD). However, recruitment in ILD clinical trials is often challenging. Certain trial characteristics may influence willingness to participate but this has not been investigated in people with ILD. This study aims to identify the factors that influence participation in clinical trials in people with ILD. Methods: This is a qualitative study using thematic analysis. Participants with ILD were recruited from a tertiary hospital in Melbourne, Australia between 2023 and 2024. Interviews were conducted over the phone, recorded and transcribed. The study was approved by the Alfred Hospital Ethics Committee (598/22). Results: 17 participants with mild-to-moderate ILD were included. Overarching themes were: 1) reasons for participation, including development of new treatments, acceptable burden of participation and positive relationship with the research team; 2) reasons for refusing participation, consisting of disruption to daily life including financial burden, impact on health and uncertainty of benefits; and 3) experience when participating, including lack of communication and poor relationship with the research team. Participants described positive experiences (care and support from the research team) and negative experiences (discontinuation of treatment, insufficient information on trial outcomes) of trial participation. Discussion: People with ILD prefer trials that offer clear information and minimise disruption to their daily routines. A unique finding in this population is the importance placed on communication and support from the research team, as well as the desire to receive feedback about the trial's outcomes.


  • Open Access

    Products, Performance, and Technological Development of Ambulatory Oxygen Therapy Devices: Scoping Review (Preprint)

    by Shohei Kawachi, Mariana Hoffman, Lorena Romero, Magnus Ekström, Jerry A Krishnan, Anne E Holland

    BACKGROUND Ambulatory oxygen therapy is prescribed for patients with chronic lung diseases who experience exertional hypoxemia. However, available devices may not adequately meet user requirements, and their performance characteristics are heterogeneous. OBJECTIVE This study aims to identify devices available for delivery of ambulatory oxygen therapy, the technologies that they use to generate oxygen, the performance characteristics of each device, and the development status. METHODS We used medical and engineering databases to identify peer-reviewed papers (eg, MEDLINE, IEEE). Gray literature was used to identify additional descriptions of ambulatory oxygen devices in military medicine, space exploration, or patents. The last search was conducted in September 2025. Documents that described a device that can deliver oxygen in an ambulatory context (defined as weighing less than 10 kg) and were written in English were included. Search results were screened for inclusion by 2 independent reviewers. Data were synthesized by descriptively mapping the performance of each product, the technology used, and the development status of emerging technologies. RESULTS From 9702 records identified, a total of 166 met eligibility criteria (106 scientific publications and 60 gray literature). We identified 33 portable oxygen concentrators (POCs; 29 commercially available), 10 oxygen cylinders, and 6 portable liquid oxygen (LOX) devices. The POC products showed a trade-off between portability and oxygen delivery capacity (maximum flow rate ranging from 2.0 to 6.0 L/min; device weight ranging from 1.0 to 9.1 kg). Pressure swing adsorption with zeolite was the most common oxygen generation technology in POCs on the market. The mean maximum continuous operating time of POCs was 3.8 hours. Two prototype POCs (maximum flow rate of 4-6 L/min and device weight of 8-9 kg) were developed for space exploration using modified adsorbents. LOX devices were the lightest and had the longest continuous operating time. Innovations in delivery included the downsizing of a POC by using nanozeolite as an adsorbent and pulse oximeter oxygen saturation (SpO2)–targeted automatic titration of oxygen delivery based on the user’s SpO2. CONCLUSIONS This scoping review is the first study to integrate medical, engineering, and gray literature on ambulatory oxygen devices and their development. Although prior literature has narratively explained the products and technologies, no previous research has systematically investigated them. This review showed that POCs available to consumers may not meet the needs of patients in terms of flow rate, portability, and operating time. LOX devices offered superior performance but are limited by high costs. Limitations of this review include the difficulty of comparing product performance across oxygen delivery settings and that the records were largely obtained from English-language sources. Innovation in ambulatory oxygen technology has been limited over the past decade, highlighting urgent need for research and development of new lightweight devices with higher oxygen delivery. CLINICALTRIAL OSF Registries 10.17605/OSF.IO/QS7FX; https://osf.io/qs7fx

  • Open Access

    What are the important components of physical activity for people with fibrotic interstitial lung disease?

    by Mariana Hoffman, Christie R. Mellerick, Angela T. Burge, Anne E. Holland

    Introduction: Fibrotic interstitial lung disease (fILD) is characterized by scarring of the lungs, decline in lung function and compromised exercise capacity. People with fILD participate in less daily physical activity compared to healthy controls, however, the relative importance of physical activity components (volume, intensity, duration) is unknown. This study aimed to examine the relationship between the components of physical activity and established disease severity and impact measures in fILD. Methods: Participant data were from baseline assessment of a randomized controlled trial recruiting people with fILD and exertional desaturation during exercise testing on room air. Physical activity components including volume (steps per day), intensity (light, moderate and vigorous) and duration (time spent in different physical activity intensities) were objectively assessed for 7 days using two physical activity monitors. Associations of these components with lung function (FVC, FEV 1 , TLCO), functional exercise capacity (6-min walk distance, 6MWD) and dyspnea (Dyspnea-12 questionnaire) were investigated. Results: 106 participants with mild to severe fILD were included. Physical activity volume was not associated with 6MWD (r = 0.027, p = 0.78) and weakly associated with lung function (FVC r = 0.33, p = 0.001; FEV 1 r = 0.34, p = 0.001). Physical activity intensity and duration were weakly associated with 6MWD (light r = 0.22 p = 0.02; moderate r = 0.42, p < 0.001; vigorous r = 0.33, p = 0.01). Time spent in vigorous physical activity was weakly associated with lung function (FVC r = 0.19, p = 0.05; FEV 1 r = 0.18, p = 0.006). Dyspnea scores were not associated with any physical activity variables. Relationships remained consistent after adjusting for age, gender and disease severity, with the exception of vigorous physical activity which was no longer associated with lung function or 6MWD. Conclusion: In people with fILD, the physical activity components of volume, intensity and duration were associated with different measures of disease severity and impact. This highlights the importance of considering specific physical activity components when evaluating and promoting physical activity in this group.

  • Similar Weaning Success Rate with High-Intensity and Sham Inspiratory Muscle Training: A Randomized Controlled Trial (IMweanT)

    by Marine Van Hollebeke, Diego Poddighe, Mariana Hoffman, Beatrix Clerckx, Jan Muller, Zafeiris Louvaris, Greet Hermans, Rik Gosselink, Daniel Langer

    Rationale: Inspiratory muscle training (IMT) improves respiratory muscle function in patients with weaning difficulties. IMT protocols involve performing daily sets of breaths against external loads. However, the impact of IMT on weaning outcomes while incorporating sham control interventions remains unclear. Objectives: To compare the effects of a high-intensity IMT (Hi-IMT) intervention with a sham low-intensity (Lo-IMT) control group on weaning outcomes and respiratory muscle and pulmonary function 28 days after inclusion in patients with weaning difficulties. Methods: Both groups underwent daily IMT sessions until successful weaning or a maximum of 28 days. The Hi-IMT group (n = 44; 61% male; aged 57 ± 15 yr) performed maximal inspirations initiated from residual volume against an external load representing 30–50% of maximal inspiratory pressure (PImax), and the control group (n = 46; 52% male; aged 60 ± 12 yr) performed maximal inspirations against a load ⩽10% PImax. Measurements and Main Results: Training adherence (completed/planned sessions) was comparable between the groups (Hi-IMT, 77 ± 20%; Lo-IMT, 72 ± 17%; P = 0.25). Weaning success (64% Hi-IMT and 76% Lo-IMT; P = 0.43) and weaning duration (Hi-IMT, 45 ± 48 d; Lo-IMT, 37 ± 26 d; P = 0.33) were similar between groups. Both groups similarly improved PImax (Hi-IMT, +15 cm H2O [95% confidence interval (CI), 9, 20]; Lo-IMT, +14 cm H2O [95% CI, 9, 19]; P = 0.72). FVC improved more in the Hi-IMT group than in the Lo-IMT group (Hi-IMT, +0.33 L [95% CI, 0.22, 0.43]; Lo-IMT, +0.16 L [95% CI, 0.07, 0.25]; P = 0.04). Conclusions: Both high-intensity IMT and sham low-intensity IMT, with high adherence to the protocol, resulted in similar weaning success rates and pronounced improvements in maximal inspiratory muscle strength. Clinical trial registered with www.clinicaltrials.gov (NCT03240263).


  • Open Access

    The impact of an early, viable, and low-cost mobilization protocol in critically ill patients: comparison with conventional physical therapy

    by Rodrigo César Maia Moreira, Rodrigo Marques Tonella, Lucinara Martins Silva Tallarico, Taís Mendes de Camargo, Liliane Patrícia Souza Mendes, Mariana Hoffman Barbosa, Maria Clara Xavier Salles, Marcelo Velloso

    This study aims to analyze the outcomes of applying an early mobilization protocol, using low-cost interventions with the minimum necessary equipment in an intensive care unit. A clinical trial, controlled and randomized, conducted in collaboration with the Laboratory for Assessment and Research in Cardiorespiratory Performance of the Department of Physical Therapy at the Federal University of Minas Gerais and the Intensive Care Unit of Risoleta Tolentino Neves Hospital in Belo Horizonte, Brazil, over a period of 5 months. Patients were randomized into two groups (treatment n=67 and control n=67). The primary outcome was days of discharge from bed. Secondary outcomes included ICU length of stay, hospital length of stay, hospitalization costs, time on mechanical ventilation, ICU mortality, and hospital mortality. The group characteristics were similar in the initial assessment. It was found that 61 patients (97%) in the treatment group were discharged from bed compared to only two patients (3%) in the control group. The proposed mobilization protocol reduced hospitalization costs by 30.27%, an approximate difference of R$7,000.00 per patient. The mean ICU stay time for the treatment group was less than the control group. There were no statistically significant differences in ICU hours, hospital length of stay, or mechanical ventilation time. The results of this study demonstrated that the application of a low-cost and minimally equipped early mobilization protocol was safe and effective for patients, promoting early discharge from bed.

  • Open Access

    O impacto de um protocolo de mobilização precoce, viável e de baixo custo em pacientes críticos: comparação com a fisioterapia convencional

    by Rodrigo César Maia Moreira, Rodrigo Marques Tonella, Lucinara Martins Silva Tallarico, Taís Mendes de Camargo, Liliane Patrícia Souza Mendes, Mariana Hoffman Barbosa, Maria Clara Xavier Salles, Marcelo Velloso

    RESUMO Neste estudo foi analisado o resultado da aplicação de um protocolo de mobilização precoce, fazendo uso de intervenções de baixo custo, com o mínimo de equipamentos necessários em uma unidade de terapia intensiva. Trata-se de um ensaio clínico, controlado e randomizado, realizado em parceria com o Laboratório de Avaliação e Pesquisa do Desempenho Cardiorrespiratório do Departamento de Fisioterapia da Universidade Federal de Minas Gerais e com a Unidade de Terapia Intensiva (UTI) do Hospital Risoleta Tolentino Neves, em Belo Horizonte, Brasil, no período de cinco meses. Os pacientes foram distribuídos de forma aleatória em dois grupos (tratamento [GT] n=67 e controle [CG] n=67). O desfecho primário foram os dias de saída do leito, enquanto os desfechos secundários foram: tempo de internação na UTI, tempo de internação hospitalar, custos de internação, tempo em Ventilação Mecânica Invasiva (VMI), mortalidade na UTI e mortalidade hospitalar. As características dos grupos foram similares na avaliação inicial. Verificou-se que 61 pacientes (97%) do GT foram retirados do leito, em comparação com apenas dois pacientes (3%) do GC. O protocolo de mobilização proposto reduziu os custos de internação em 30,27%, diferença aproximada de R$7 mil por paciente. A média de tempo de estadia na UTI do GT foi menor do que a do GC. Não houve diferença estatisticamente significativa quanto às horas de permanência em UTI, tempo de permanência hospitalar e tempo de VMI. A aplicação do protocolo de mobilização precoce de baixo custo e com o mínimo de equipamentos foi segura e eficaz para os pacientes, promovendo a saída precoce do leito.


  • Open Access

    A self-management package for pulmonary fibrosis: A feasibility study

    by Joanna Y.T. Lee, Gabriella Tikellis, Mariana Hoffman, Christie R. Mellerick, Karen Symons, Janet Bondarenko, Yet H. Khor, Ian Glaspole, Anne E. Holland


  • Open Access

    The Alfred Health post‐COVID‐19 service, Melbourne, 2020–2022: an observational cohort study

    by Anne E Holland, Daniel Fineberg, Tunya Marceau, Melissa Chong, Jessica Beaman, Lisa Wilson, Jo‐Anne Buchanan, Jacqueline Uren, Simone Dal Corso, Natasha A Lannin, et al.

    Objectives: To determine the uptake of the Alfred Health Post‐COVID service among people hospitalised with coronavirus disease 2019 (COVID‐19) or referred by general practitioners; to describe their characteristics and symptoms at eight weeks and the clinical services they required.Study design: Observational cohort study.Setting: Outpatient post‐COVID‐19 follow‐up service in a tertiary Melbourne hospital.Participants: All people admitted to Alfred Health (inpatients, hospital‐in‐the‐home) with COVID‐19, 19 March 2020 – 28 December 2022; people with persistent symptoms referred by general practitioners in the Alfred Health catchment area during 2022.Intervention: Questionnaire‐based symptom assessment eight weeks after onset of COVID‐19. Dyspnoea, fatigue, depression, anxiety, and post‐traumatic stress disorder were assessed with standardised tools, as were health status and health‐related quality of life; return to work or study, weight loss, and altered cognition and memory were also assessed. Screening was followed by physical assessment and management at the service (specialist general medicine review, physiotherapist, allied health assistant, neuropsychologist) and referral to other specialist medical services as required.Main outcome measures: Proportion of eligible people who used the service for follow‐up at eight weeks; proportions of service users who reported symptoms and return to pre‐COVID‐19 employment or study; clinical services required by service users.Results: Of 6712 people invited for screening, 726 completed questionnaires (11%). At least one persistent symptom was reported by 385 of 642 respondents (60% of respondents, 5.7% of invitees), most frequently memory (371 of 656, 57%) or concentration problems (431 of 656, 66%), dyspnoea (197 of 703, 28%), and extreme fatigue (189 of 673, 28%). Sixty‐seven of 453 respondents had not returned to pre‐COVID‐19 work or study (15%). People were referred to a variety of medical and non‐medical services for management, including specialist medical clinics, allied health, and rehabilitation. Among 71 people who also completed questionnaires at twelve months, the proportions who reported fatigue, anxiety, and memory and concentration changes were similar at both assessments.Conclusions: After acute COVID‐19 that required hospital admission or was followed by persistent symptoms in community care, a small proportion of people (5.7%) reported symptoms that required medical and allied health specialist assessment and management. Our findings may assist planning services for people with long COVID.